LNSLNS

We thank Dr. Tsamaloukas for enriching our comprehensive list of differential diagnoses of chronic recurrent aphthous ulcers (1).

The “ulcerations and oral gangrene” affecting some patients with acatalasemia (Takahara’s disease)—a rare enzymopathy (estimated prevalence 1:31 250) (2) that is usually asymptomatic and has an autosomal recessive pattern of inheritance—are pronounced hemorrhagic mucosal necroses and ulcerations caused by H2O2 (3). For this reason, acatalasemia should be added to the group of “Other oral disorders” in our list.

We also thank Dr. Glaenz for his comment. We consider the reduction of neutrophil granulocytes in the epidermis and corium (4) and of the total lymphocyte number in the peripheral blood (5), that is caused by fumaric acid, as a possible mechanism of action of fumaric acid esters in chronic recurrent aphthous ulcers. These events may be interpreted in the sense of an immunosuppressant effect (5).

Because of the large number of reported therapeutic approaches in chronic recurrent aphthous ulcers, however, we felt obliged to only include those therapeutic schemes in our article that have a higher evidence level (1). This didactic approach did not aim to cast aspersions on the value of such therapies, which in spite of long years of positive clinical experiences have not been considered in the planning of evidence based studies.

DOI: 10.3238/arztebl.2015.0222c

Prof. Dr. med. Prof. h.c. Dr. h.c. Christos C. Zouboulis

Klinik für Dermatologie,
Venerologie und Allergologie/Immunologisches Zentrum,
Städtisches Klinikum Dessau

christos.zouboulis@klinikum-dessau.de

Conflict of interest statement

The authors of all contributions declare that no conflict of interest exists.

1.
Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC: The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int 2014; 111: 665–73 VOLLTEXT
2.
Orphante, das Netz für seltene Krankheiten und orphan drugs. Akatalasämie. www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=DE&Expert=926 (last accessed on 14 January 2015).
3.
Perner H, Krenkel C, Lachner B, Hintner H, Hawranek T: Akatalasämie – Morbus Takahara. Hautarzt 1999; 50: 590–2 CrossRef MEDLINE
4.
Bacharach-Buhles M, Pawlak FM, Matthes U, Joshi RK, Altmeyer P: Fumaric acid esters (FAEs) suppress CD 15– and ODP 4-positive cells in psoriasis. Acta Derm Venereol Suppl 1994; 186: 79–82 MEDLINE
5.
Altmeyer P, Nuchel CM: Fumarate zur Behandlung der Psoriasis. Dtsch Arztebl 1996; 93: A-3194 VOLLTEXT
1.Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC: The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int 2014; 111: 665–73 VOLLTEXT
2.Orphante, das Netz für seltene Krankheiten und orphan drugs. Akatalasämie. www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=DE&Expert=926 (last accessed on 14 January 2015).
3.Perner H, Krenkel C, Lachner B, Hintner H, Hawranek T: Akatalasämie – Morbus Takahara. Hautarzt 1999; 50: 590–2 CrossRef MEDLINE
4.Bacharach-Buhles M, Pawlak FM, Matthes U, Joshi RK, Altmeyer P: Fumaric acid esters (FAEs) suppress CD 15– and ODP 4-positive cells in psoriasis. Acta Derm Venereol Suppl 1994; 186: 79–82 MEDLINE
5.Altmeyer P, Nuchel CM: Fumarate zur Behandlung der Psoriasis. Dtsch Arztebl 1996; 93: A-3194 VOLLTEXT

Info

Specialities